Danish Life Science Leaders and US Investors to Meet on Cross-Border Development Events, featured, NewsBack Bay Life Science AdvisorsMarch 28, 2018Biotech, DKBIO2018, Life sciences seminar
Xconomy: Proxima Aims to Fill CRO Gap for Houston’s Growing Biotech Community Jonathan Gertler Posts, News, Back Bay in the Newsjonathan gertlerMarch 14, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Life Science Leader: Dynamics and Value of Cross-Border Biotech Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsMarch 1, 2018Biotech, cross-border, Denmark, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
STAT: Biosimilars, The Cure for Sky-High Drug Prices or a Stake in the Heart of Innovation? Michelle Hoffmann Posts, NewsBack Bay Life Science AdvisorsFebruary 9, 2018Biosimilars, Biotech, Michelle Hoffmann
What Should Be Done About the Shrinking Number of US Public Companies? Blog, Greg Benning Posts, NewsInvestment Banking TeamFebruary 6, 2018Finance, Greg Benning, JP Morgan, JPM, Public companies
Fierce CEO: Back Bay Life Science Advisors CEO Helps Healthcare Companies Grow featured, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJanuary 29, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
White Paper: US Biosimilars 2018: Opportunities and Challenges News, WhitepapersBack Bay Life Science AdvisorsJanuary 3, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
MedCity News: Back Bay Life Science Advisors on Reproductive Health Genetic Testing Market Chris Leo Posts, NewsBack Bay Life Science AdvisorsOctober 6, 2017Genetic testing, MedCity, Prenatal testing, Reproductive health
Back Bay Life Science Advisors to Lead BioNetwork West Partnering Summit October 23-25 Chris Leo Posts, Events, Jonathan Gertler Posts, Michelle Hoffmann Posts, NewsBack Bay Life Science AdvisorsOctober 3, 2017BioNetwork Partnering Summit, BioNetwork West, Biotechnology
Wall Street Journal Pro Venture Capital: Back Bay’s Jonathan Gertler Comments on Biotech IPO Market Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsOctober 3, 2017Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Back Bay Life Science Advisors and Gorrissen Federspiel Life Sciences Seminar Events, NewsBack Bay Life Science AdvisorsSeptember 26, 2017Biotech, Life sciences seminar
Pharma Letter: Rare Disease Drug Development Michelle Hoffmann Posts, NewsBack Bay Life Science AdvisorsSeptember 11, 2017Population health, The future of rare disease drug development, The Pharma Letter
PharmaVOICE: Drug-Device Combination Development News, Steve Gauldie PostsBack Bay Life Science AdvisorsSeptember 7, 2017Drug device combination development, PharmaVOICE
Wall Street Journal: Rise of Earnouts Muddies M&A Waters Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsAugust 30, 2017Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Precision Medicine and the Age of Collaboration Blog, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsAugust 7, 2017Biotech, healthcare, Jonathan Gertler, Precision medicine
Boston Business Journal: A Potential Inflection Point for Biogen Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 20, 2017Biotech, Boston Business Journal, IPO, Jonathan Gertler
Boston Globe: The End of the IPO Drought Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 4, 2017Biotech, Boston Globe, IPO, Jonathan Gertler
Back Bay Biopharma Confidence Index Blog, Chris Leo Posts, Greg Benning Posts, NewsInvestment Banking TeamJune 6, 2017
BioPharma Puts Skin in Atopic Dermatitis Game: Strategy/Transaction Insights News, Peter Bak Posts, Steve Gauldie PostsBack Bay Life Science AdvisorsMay 2, 2017
Back Bay Life Science Advisors CEO Jonathan Gertler to Moderate Precision Medicine Panel Discussion with John Quackenbush and Geoffrey McDonough Events, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsMay 2, 2017
